KC
TBIO

KCL Capital’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

KCL Capital’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-566
Closed -$110K – 74
2021
Q4 		$110K Sell
566
-450
-44% -$70K 0.01% 56
2021
Q3 		$204K Sell
1,016
-373
-27% -$94.7K 0.01% 47
2021
Q2 		$550K Buy
+1,389
New +$491K 0.08% 41

Other funds holding TBIO

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
OAM
Ophir Asset Management Sydney, Australia $859M AUM 59.08% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCL Capital's TBIO Position: Q1 2022 in Review

KCL Capital sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q1 2022, closing a stake of 566 shares — an estimated $110K sold.

KCL Capital first reported a position in TBIO in Q2 2021 and held it in 3 quarters. The position peaked at $550K in Q2 2021. 47 funds tracked by Wall St. Rank hold TBIO as of Q1 2022.

  • KCL Capital reported no remaining Telesis Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • KCL Capital sold 566 Telesis Bio, Inc. Common Stock shares in Q1 2022, an estimated $110K.
  • KCL Capital first reported a position in Telesis Bio, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • KCL Capital's Telesis Bio, Inc. Common Stock position peaked at $550K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q1 2022.

Based on KCL Capital's 13F filing for Q1 2022, filed 16 May 2022.